DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comtan (Entacapone) - Summary

 
 



COMTAN SUMMARY

Comtan® (entacapone) is available as tablets containing 200-mg entacapone.

Comtan (entacapone) is indicated as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's Disease who experience the signs and symptoms of end-of-dose "wearing-off" (see CLINICAL PHARMACOLOGY, Clinical Studies).

Comtan's effectiveness has not been systematically evaluated in patients with idiopathic Parkinson's Disease who do not experience end-of-dose "wearing-off".


See all Comtan indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Comtan (Entacapone)

Drug discovery for Parkinson's disease: LCSB researchers grow neurons in 3-D
Source: Neurology / Neuroscience News From Medical News Today [2015.06.26]
The progressive loss of neurons in the brain of Parkinson's patients is slow yet inexorable. So far, there are no drugs that can halt this insidious process.

New study calls for partnering of Parkinson's disease research community with patient groups to improve effectiveness of clinical trials
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.06.25]
Despite an urgent need for new medications, clinical trials in Parkinson's disease (PD) have a relatively low rate of success.

New knowledge: Parkinson's disease may begin in the gut
Source: GastroIntestinal / Gastroenterology News From Medical News Today [2015.06.24]
A major epidemiological registry-based study from Aarhus University and Aarhus University Hospital indicates that Parkinson's disease begins in the gastrointestinal tract; the study is the largest in...

New Med Reduces Psychosis in Parkinson's Disease Patients
Source: MedPage Today Psychiatry [2015.06.19]
(MedPage Today) -- Pimavanserin appears safe across multiple phase III trials

Phase III data released for NUPLAZID (pimavanserin) for Parkinson's disease psychosis
Source: Clinical Trials / Drug Trials News From Medical News Today [2015.06.18]
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, have...

more news >>

Published Studies Related to Comtan (Entacapone)

Entacapone augmentation of antipsychotic treatment in schizophrenic patients with negative symptoms; a double-blind placebo-controlled study. [2014]
Negative symptoms in schizophrenia are associated with decreased dopaminergic activity in the prefrontal cortex (PFC). It is hypothesized that increasing dopamine levels would alleviate negative symptoms...

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. [2011.01]
OBJECTIVE: In Parkinson disease (PD), the selective C-O-methyltransferase (COMT) inhibitor entacapone prolongs the effect of levodopa on motor symptoms (ON time) by increasing its bioavailability. The COMT Val158Met polymorphism is equally distributed in PD patients and modulates COMT activity, which can be high (Val/Val, COMT(HH) ), intermediate (Val/Met, COMT(HL) ), or low (Met/Met, COMT(LL) ). The objective of this study was to determine the response to entacapone in COMT(HH) and COMT(LL) PD patients... INTERPRETATION: The COMT(HH) genotype in PD patients enhances the effect of entacapone on the pharmacodynamics and pharmacokinetics of levodopa. The response to entacapone after repeated administrations and in heterozygous patients remains to be determined. Copyright (c) 2010 American Neurological Association.

Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. [2011.01]
BACKGROUND: L-threo-3,4-dihydroxyphenylserine (L-DOPS), a norepinephrine (NE) prodrug, is investigational for orthostatic hypotension, which occurs commonly in Parkinson's disease. Adjunctive anti-parkinsonian drugs might interact with L-DOPS. We tested whether L-aromatic amino-acid decarboxylase inhibition by carbidopa (CAR) attenuates L-DOPS conversion to NE and blocks the pressor effect of L-DOPS, whereas catechol-O-methyltransferase inhibition by entacapone (ENT) interferes with L-DOPS metabolism and augments the pressor effect... CONCLUSIONS: After L-DOPS administration plasma, NE levels do not increase sufficiently to increase blood pressure. Pressor responses to L-DOPS seem to reflect NE produced extraneuronally that escapes extensive enzymatic deamination and O-methylation and evokes vasoconstriction before reaching the systemic circulation.

Effects of carbidopa and entacapone on the metabolic fate of the norepinephrine prodrug L-DOPS. [2011]
interferes with L-DOPS metabolism and augments the pressor effect... CONCLUSIONS: After L-DOPS administration plasma, NE levels do not increase

Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. [2010.11]
OBJECTIVE: Controlled-release levodopa/carbidopa (CR-LC) is often used to provide prolonged control of night-time motor symptoms in patients with Parkinson's disease (PD). Levodopa/carbidopa/entacapone (LCE) provides higher bioavailability of levodopa compared with levodopa/carbidopa formulations and has been shown to be effective in PD patients with wearing-off symptoms. The aim of this study was to compare the bioavailability of levodopa after a single evening dose (administered at 10 p.m.) of LCE 200 or CR-LC 200... CONCLUSIONS: The results of this study demonstrate that a single bedtime dose of LCE 200 provides higher bioavailability of levodopa compared to CR-LC 200.

more studies >>

Clinical Trials Related to Comtan (Entacapone)

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers [Completed]

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers [Completed]

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone in Healthy Volunteers [Completed]

Bioequivalence Study of Carbidopa/Levodopa/Entacapone Combination vs. Carbidopa/Levodopa Combination Plus Entacapone Under Fasting Conditions in Healthy Volunteers [Completed]

Carbidopa/Levodopa/Entacapone Versus Immediate Release (IR) Carbidopa/Levodopa on Non-Motor Symptoms in Patients With Idiopathic Parkinson's Disease [Recruiting]
The purpose of this study is to test the effects of carbidopa/levodopa/entacapone compared to the effects of immediate-release carbidopa/levodopa on end-of-dose wearing off in persons who have Parkinson's disease.

more trials >>

Reports of Suspected Comtan (Entacapone) Side Effects

Dysphagia (8)Pain in Extremity (8)Blood Creatine Phosphokinase Increased (6)Parkinson's Disease (6)Abnormal Behaviour (6)Dyskinesia (5)Muscle Spasms (5)Chromaturia (5)Akinesia (5)Tremor (5)more >>


Page last updated: 2015-06-26

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015